Merck has developed a drug which, in trials, has halved the hospitalisation rate. The trials have been stopped. This is often done when a drug is shown to be so effective that it would be unethical to give half the patients in the trial an ineffective placebo.
FT.com writes:
"Merck said it would ask US regulators to authorise the first antiviral pill to treat Covid-19 after a late-stage clinical trial showed the drug cut the risk of hospitalisation or death in half...."
"...The US pharmaceuticals company said on Friday that it had stopped the phase 3 clinical trial early after an interim analysis showed that 7.3 per cent of patients on the drug had died or been hospitalised, versus 14.1 per cent of those receiving a placebo.
The decision to halt the study was taken following a recommendation from an independent committee of scientists monitoring the trial and after consultations with the FDA.
The interim analysis of data from 775 patients showed that none of the participants receiving molnupiravir had died during the first 29 days of the study, versus eight who received a placebo, Merck said."
FT.com writes:
"Merck said it would ask US regulators to authorise the first antiviral pill to treat Covid-19 after a late-stage clinical trial showed the drug cut the risk of hospitalisation or death in half...."
"...The US pharmaceuticals company said on Friday that it had stopped the phase 3 clinical trial early after an interim analysis showed that 7.3 per cent of patients on the drug had died or been hospitalised, versus 14.1 per cent of those receiving a placebo.
The decision to halt the study was taken following a recommendation from an independent committee of scientists monitoring the trial and after consultations with the FDA.
The interim analysis of data from 775 patients showed that none of the participants receiving molnupiravir had died during the first 29 days of the study, versus eight who received a placebo, Merck said."